H.C. Wainwright reaffirmed its Buy rating and $30.00 price target for NASDAQ:OCS, the stock of Oculis Holding AG. Following the company's disclosure of its second-quarter financial performance, the firm reiterated its stance. Oculis reported revenue of CHF 245K and a net loss of CHF 20.8 million, equivalent to CHF 0.51 per share.
The update from Oculis also included significant regulatory developments. The company has engaged with the FDA in a pre-NDA meeting concerning OCS-01, a topical formulation of dexamethasone intended for once-daily use to treat inflammation and pain after ocular surgery.
The FDA has indicated that the data from the completed Phase 3 OPTIMIZE-1 trial, the Phase 2 SKYGGN trial, and safety data from other completed trials in ocular surgery and diabetic macular edema (DME) are adequate to support a New Drug Application (NDA) submission.
Additionally, the firm noted that the Phase 3 OPTIMIZE-2 trial for OCS-01 is being concluded. The analyst highlighted the potential of OCS-01 to become the first once-daily, preservative-free steroid treatment for post-operative inflammation and pain.
The reaffirmation of the Buy rating and price target comes amidst these developments, with the analyst expressing confidence in the potential of OCS-01 and its upcoming regulatory submission. The company's financial results and the progress in its clinical trials and regulatory interactions were central to the firm's reiterated position on the stock.
In other recent news, Oculis Holding AG has been making significant strides in its operations and financial standing. The biopharmaceutical company recently appointed Dr. Sharon Klier as CDO, a move that is expected to bolster its ophthalmology pipeline.
Financial firms H.C. Wainwright, Baird, and BofA Securities have all adjusted their price targets for Oculis. H.C. Wainwright raised its price target for Oculis to $30, while Baird increased its price target to $37 following promising results from a Phase 2 study on dry eye disease.
BofA Securities reduced the price target to $20, despite increasing the odds of success for the OCS-02 program to 55% based on the findings.
Oculis has also reported a successful equity financing round, generating gross proceeds of approximately $59 million. This, along with a recent securities offering by Enlivex expected to generate $15 million, is projected to sustain the company's operations into 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.